中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (1) :31-34    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
Ѫ֬����ѹ�����ɵ����ļ��ع��ı�������
��ѩ�꣬�������Ű�����̷��
�ൺ��ѧҽѧԺ����ҽԺ���ڿƣ�ɽ�� �ൺ 266003
ZHANG Xue-juan��SONG Li��ZHANG Ai-fang�� TAN Kai
Department of Cardiology�� Affiliated Hospital of Qingdao Medical University�� Qingdao 266003�� China

Download: PDF (871KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �۲�Ѫ֬����ѹ�����ɵ����ļ��ع���Ӱ�죬��̽������ܵĻ��ơ����� 12��������Wistar����40ֻ������200��250 g�������Ϊ4�飬�����������顢�������顢�ļ��ʺ��顢Ѫ֬���顣Ѫ֬������������Ѫ֬��0.09 g��kg-1��d-1����ҩ�ﰴ1 mL��100 g-1����������ˮ��θ��1 d1�Σ��������ÿ��1 mL��100 g-1������ˮ��θ��ͨ����խ�������������� �Ʊ������ļ��ʺ�ģ�ͣ���ʵ���յ��ڸ�ǻ������Ѫ������Ѫ�壬����ϸ������1-�£�IL-1�¡���ϸ������-4��IL-4�ĺ���������ʵ������������󣬲ⶨ������/���ء�������/���صı�ֵ��������Ƭ���ұں�Ⱥ��ļ�ϸ��ֱ������� �ļ��ʺ�������ѹ���Ը������������飨P<0.05����Ѫ֬����Ѫѹ�������½��������ļ��ʺ�����Ȳ�����ͳ��ѧ���壨P>0.05���ļ��ʺ������������/������������������/��������Ѫ��IL-1�º��������ұں�ȼ��ļ�ϸ��ֱ�������Ը������������飨P<0.01��Ѫ֬�������ƺ�����ָ��������½���P<0.01���������������鼰��������������������죨P>0.05�����ļ��ʺ���Ѫ��IL-4 �ĺ�������������Ѫ֬���飨P<0.01������ Ѫ֬����ѹ�����ɵ��µ��ļ��ع��������Եı������ã�ͬʱ������������ˮƽ�Ľ��ͣ�˵��Ѫ֬���ı������ÿ������俹�������йء�
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� Ѫ֬��   �ļ��ع�   ��������   ��֢     
Abstract�� OBJECTIVE To investigate the protective effect of Xuezhikang on the myocardial hypertrophy caused by pressure overload and it��s mechanism in rats. METHODS 40 wistar rats were randomized into myocardial hypertrophy group�� Xuezhikang group �� fake operation group and control group. Pressure overload was achieved by surgical constricting the abdominal aortal. After the operation the rat in drug group were treated with Xuezhikang by intragastric administration (0.09 g��kg-1 d�� the others were treated with normal saline by intragastric administration at the same time. ALL rats were sacrificed 8 weeks after the operation then the heart weight to body ratio and left ventricular weight to body ratio were measured . Blood samples were extracted from the abdominal vein of the animals��and the sera were collected with hypothermia high speed centrifugation for the measurement of interleukin-1�� and interleukin-4. RESULTS Systolic blood pressure(SBP in myocardial hypertrophy group were significantly higher than that in control group��while in the Xuezhikang group SBP has no significant difference compared with the myocardial hypertrophy group��P>0.05.The heart weight to body ratio�� the left ventricular weight to body�� the levels of serum IL-1�£� the thickness of left ventricular wall and the diameters of cadiocytes in myocardial hypertrophy group were significantly higher than that in control group. These indexes were significantly decreased after treatment with Xuezhikang�� but compared with control group and sham operation group�� there were no difference among them; while the levels of IL-4 in Xuezhikang group were higher significantly than those in myocardial hypertrophy group(P<0.01. CONCLUSION Xuezhikang can prevent the myocardial hypertrophy caused by pressure overload and that may attribute to its anti-inflammation effect.
Keywords�� Xuezhikang,   myocardial reconstitution,   protective effect,   inflammation     
�ո�����: 2011-11-11;
���ñ���:   
.Ѫ֬����ѹ�����ɵ����ļ��ع��ı�������[J]  �й�ҩѧ��־, 2011,V46(1): 31-34
.The Effect of Xuezhikang on Myocardial Hypertrophy Caused by Pressure Overload[J]  Chinese Pharmaceutical Journal, 2011,V46(1): 31-34
��
û�б��IJο�����
[1] ½���� ���� .�鵰��ȥ������ø���Ƽ��ڷ�����������о���չ[J]. �й�ҩѧ��־, 2012,47(5): 321-324
[2] ������ ������ Ԭ���� ����Ӣ ��ɺɺ ��ʿ�� ������ .����������׻�������D-�����ǰ��յ���С���Ը����˵ı�������[J]. �й�ҩѧ��־, 2011,46(24): 1898-1900
[3] ������ ������ ������ ����.ά����D�����������ǻ�����ҩ�������о���չ[J]. �й�ҩѧ��־, 2011,46(22): 1700-1703
[4] �Ҵ��� ���� ���� ��С�� �¼Ѻ� ̷������HT.ϸ����Ĥ���ںϵ���PEP1-vMIP-��ٽ�Ѫ�������о�[J]. �й�ҩѧ��־, 2011,46(11): 809-813
[5] ��ѩ�� ��ë�� ����.Ѫ֬���Դ����ļ�ȱѪ�ٹ�ע���˵ı�������[J]. �й�ҩѧ��־, 2010,45(13): 1002-1004
[6] ����Ц Īѩ÷ ���� ����Ӣ �Ź�.ӫ�ⶨ��PCR���о����鲡������ϸ����֢����������ҩ���⿹HIV-1������[J]. �й�ҩѧ��־, 2010,45(11): 814-817
[7] ��� ;������;�ź���;������;��ѩ��;����.������A��תҰ�ٺϼ����յ����������ع�[J]. �й�ҩѧ��־, 2009,44(14): 1070-1073
[8] ����ӱ;����;��ΰ.��������ɳ�涡�������Զ���ʵ����θ���񼰼��Զ���ʵ���Ӱ��[J]. �й�ҩѧ��־, 2009,44(10): 759-761
[9] κ��;κΰ.���ζ��նԴ���ԭ�Թؽ��׵���������[J]. �й�ҩѧ��־, 2008,43(10): 746-750
[10] ������;������;��ά��c.����ʹ������ƥ�������ù�ض����������Ӱ��ʵ��[J]. �й�ҩѧ��־, 2008,43(07): 511-513
[11] �����;����.���Ծ����ڶ����´���ȫ����֢��Ӧ�ۺ�����Ӱ��[J]. �й�ҩѧ��־, 2006,41(15): 1142-1144
[12] ������ ;������.��֢�Գ����Ľ᳦���������ͽ᳦��λ��ҩ[J]. �й�ҩѧ��־, 2006,41(02): 86-90
[13] Ҷϣ��;³�İ�;������;���;��ҫ��.ɳ��Ѫ֬������Ѫ֬Ԥ��֬���ε�ʵ���о�[J]. �й�ҩѧ��־, 2005,39(24): 1865-1867
[14] ���;�ſ���;����Ң;����ǫ.��޼«����PPAR-�ü������õ��о�[J]. �й�ҩѧ��־, 2005,39(12): 905-907
[15] �����;����ɽ;����ѧ.��ϸ������-4���о���չ[J]. �й�ҩѧ��־, 2005,39(10): 721-725
Copyright 2010 by �й�ҩѧ��־